Pharmaceuticals News & Press Release Distribution

Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma

NANJING, China, Nov. 6, 2024 /PRNewswire/ -- On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with glo...

2024-11-06 15:20 2088

QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 SITC 39th Annual Meeting

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅱ Clinical Da...

2024-11-06 13:00 2832

Duoning Biotech announced strategic partnership with Branca Bunús to promote the next generation of transfection reagents

SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development, optimization, and application of transfection reagents, ...

2024-11-06 09:24 2071

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-11-06 09:08 2455

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-11-06 08:30 2572

MedAdvisor Solutions Launches Telehealth Service on MedAdvisor Patient App, Further Enhancing Access to Care

Patients can now book virtual provider consultations within the App MELBOURNE, Australia, Nov. 6, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today that new Telehealth functionality is now available within the MedAdvisor ...

2024-11-06 06:47 2490

Dong'e Ejiao Continues to Propel Traditional Chinese Medicine onto the Global Stage

Harnessing Tradition and Innovation: Dong'e Ejiao's Seventh Appearance at the CIIE SHANGHAI, Nov. 5, 2024 /PRNewswire/ -- On November 5th, the 7th China International Import Expo (CIIE) opened inShanghai. A key player in China Resources Group's healthcare sector, Dong'e Ejiao Co., Ltd. (hereinaf...

2024-11-05 18:09 2406

Dong'e Ejiao Continues to Propel Traditional Chinese Medicine onto the Global Stage

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

- Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST ProfessorJoung Ho Kim join a pioneering collaboration in precision oncology. SEOUL, South Korea, Nov. 5, 2024 /PRNewswire/ -- On November 4, 2024, J INTS BIO hosted a significant MOU signing ceremony at Baek...

2024-11-05 17:38 1622

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that its release of...

2024-11-04 19:00 2614

111, Inc. Announces Change to Board of Directors

SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that Dr. Leon Lian ...

2024-11-04 18:00 2601

Embrace Autumn Outdoor Activities: Renowned Traditional Chinese Medicine Expert Professor Tinly Wong Tin-Chee Offers Effective Solutions for Relieving Post-Exercise Muscle Soreness with Massage, Herbal Oils, and Plasters

HONG KONG, Nov. 4, 2024 /PRNewswire/ -- As autumn settles in and temperatures begin to drop, many individuals embrace outdoor activities such as running, cycling, and hiking, delighting in the beauty of nature. However, post-exercise muscle soreness can become a common challenge for those who typ...

2024-11-04 09:00 4470

Embrace Autumn Outdoor Activities: Renowned Traditional Chinese Medicine Expert Professor Tinly Wong Tin-Chee Offers Effective Solutions for Relieving Post-Exercise Muscle Soreness with Massage, Herbal Oils, and Plasters

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

MELBOURNE, Australia, Nov. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement bythe United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals[1] ...

2024-11-04 06:07 2710

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Nov. 2, 2024 /PRNewswire/ -- October 29, 2024, Ping An Healthcare Technology Co.,Ltd. successfully obtained the Digital Health Certificate (DHC) from the World Organization of Family Doctors (WONCA) and the WONCA Family Doctor Development & Enhancement (DEP) Certificate fo...

2024-11-03 01:39 4144

The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024

WASHINGTON, Nov. 1, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve Pl...

2024-11-01 21:00 2844

DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology

* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation * Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- OnOctober 30, a Ko...

2024-11-01 21:00 5028

The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved

SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by th...

2024-11-01 19:04 3811

HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update

* HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of430 million KRW. * Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected inNovember 2024. ROCKVILLE, Md. and SEOUL, Sout...

2024-11-01 19:00 3235

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr.Yiu-Lian Fong to the board of directors for Din...

2024-11-01 15:28 2774

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab

HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to comp...

2024-11-01 11:34 2439

CARsgen® U.S. Clinical Holds Lifted by FDA

SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration ("FDA") lifted the clinica...

2024-11-01 09:33 2812